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Cancer is a traitorous archenemy that threatens our survival. Its ability to evade detec-
tion and adapt to various cancer therapies means that it is a moving target that becomes
increasingly difficult to attack. Through technological advancements, we have developed
sophisticated weapons to fight off tumor growth and invasion. However, if we are to stand
a chance in this war against cancer, advanced tactics will be required to maximize the
use of our available resources. Oncolytic viruses (OVs) are multi-functional cancer-fighters
that can be engineered to suit many different strategies; in particular, their retooling can
facilitate increased capacity for direct tumor killing (oncolytic virotherapy) and elicit adap-
tive antitumor immune responses (oncolytic immunotherapy). However, administration of
these modified OVs alone, rarely induces successful regression of established tumors.This
may be attributed to host antiviral immunity that acts to eliminate viral particles, as well as
the capacity for tumors to adapt to therapeutic selective pressure. It has been shown that
various chemotherapeutic drugs with distinct functional properties can potentiate the anti-
tumor efficacy of OVs. In this review, we summarize the chemotherapeutic combinatorial
strategies used to optimize virally induced destruction of tumors. With a particular focus
on pharmaceutical immunomodulators, we discuss how specific therapeutic contexts may
alter the effects of these synergistic combinations and their implications for future clinical
use.
Keywords: oncolytic virotherapy, cancer immunotherapy, cancer vaccines, combination therapy, drug therapy,
combination, oncolytic viruses
Do not repeat the tactics, which have gained you one victory,
but let your methods be regulated by the infinite variety of
circumstances.
–Sun Tzu, The Art of War
INTRODUCTION
Oncolytic viruses (OVs) can selectively infect, replicate in, and
kill tumor cells with minimal impact on normal tissue. These
tumor-specific properties, called oncotropism, is dependent on the
expression of surface receptors that allow viral binding and entry,
as well as, the permissiveness of the tumor cell toward viral repli-
cation. Genetic manipulation of the viral genome aims to improve
the inherent therapeutic value of OVs by enhancing their capacity
for targeted tumor killing (1, 2). Through transgene insertion, OVs
can serve as directed gene-delivery vehicles, and thus accommo-
date a diverse array of therapeutic strategies. Arming OVs with
additional weaponry, such as pro-apoptotic genes, tumor sup-
pressors, or genes stimulating antitumor immunity, can enhance
their killing capacity. With a broad arsenal, modified-OVs have the
potential to target a wide spectrum of different cancer types. How-
ever, administration of OVs as a monotherapy has demonstrated
varying degrees of success in clinical trials (3–5). This is likely
due to host antiviral immune-mediated mechanisms that limit
OV dissemination and promotes pre-mature viral clearance. Over
an extended period, selective pressure on heterogeneous tumor
populations can also lead to therapeutic resistance to OVs via
receptor loss or mutation of essential signaling pathways required
for viral replication (6). To overcome these barriers,many clinically
established and novel chemotherapeutics have been used in com-
bination with oncolytic virotherapy, showing synergistic effects
that potentiate tumor killing (7–9). In this review, we summarize
how immunomodulatory chemotherapeutic combinatorial strate-
gies have been used to optimize virally induced destruction of
tumors and discuss their implications for future directions and
clinical use.
MECHANISMS OF ONCOLYTIC VIRUSES
TUMOR TROPISM AND ONCOLYSIS
The oncotropism of viruses is guided by cell surface receptors
that enable viral binding and entry, and the permissiveness of the
infected cell to viral replication. Surface receptors that are recog-
nized by different types of viruses can be specific to neoplastic
cells. These viruses target receptors characteristic of malignant
phenotypes, such as Poliovirus that binds CD-155 that is almost
exclusively present in high grade glioma cells (10, 11), and Sindbis
virus that recognizes high-affinity laminin receptor overexpressed
in many cancers (12). Other viruses, such as vesicular stomatitis
virus (VSV) exhibit a remarkably robust and pantropic selectiv-
ity by binding to the ubiquitously expressed LDL receptor (13).
Therefore, instead of relying on receptor specificity, tumor tropism
of VSV is dependent on the permissiveness of malignant cells to
viral infection. VSV belongs to a class of interferon (IFN)-sensitive
www.frontiersin.org June 2014 | Volume 4 | Article 145 | 1
Nguyen et al. Future perspectives of chemoviral oncotherapy
viruses, which preferentially infects tissues exhibiting reduced
or absent IFN responsiveness (14–17). This is a typical feature
of tumors, which often acquire defects in pathways involved in
innate antiviral immunity, such as the IFN pathway, as a mecha-
nism for immune escape. In fact, many of the biological pathways
altered by viral infection are similar to cellular changes acquired
during carcinogenesis. For instance, mutated oncogenes such as
BRAF or Cyclin A, increases the infectivity of VSV and parvovirus,
respectively (18, 19). As well, impaired apoptotic ability typically
observed in neoplastic cells provides an opportunity for OVs to
enhance their replicative capacity (20).
Selective retargeting of viruses to tumor cells can also be gen-
erated in viruses without innate oncolytic abilities. Adenovirus
(Ad)-based vectors are a good demonstration of this approach,
since they possess a wide tropism, but a lytic life cycle that
can be exploited for oncolytic virotherapy (21). One method to
restrict viral replication to tumor cells is the modification of E1A
and E1B genes that results in conditionally replicative Ad. As a
result, selective replication occurs in cells defective in p53 or Rb
tumor suppressor pathways; a characteristic observed in 50% of
human cancers (22). Alternatively, various transductional retar-
geting strategies exist that largely involve fusing tumor targeting
ligands to the Ad fiber knob domain, summarized in Ref. (23).
Viral oncolysis directly destroys tumor cells through either their
lytic replication cycle or the expression of endogenous cytotoxic
gene products (24). To further enhance their oncolytic effects,
transgenes encoding pro-apoptotic proteins are inserted into OVs
to subvert cell death machinery. These proteins include various
death-inducing ligands such as TNF-related apoptosis-inducing
ligand (TRAIL) (25, 26), Fas ligand (FasL) (27), and tumor sup-
pressor genes (e.g., p53, p16) (28, 29). Alternatively, small hairpin
RNA targeting factors can be inserted to silence genes involved in
cell survival or proliferation, including hTERT and ki67 (30) or
MYCN oncogene (31). Oncolytic viral infection can also induce
autophagy, a conserved catabolic process crucial in maintaining
cellular homeostasis (32). Cellular autophagy machinery is dis-
rupted by certain viruses to facilitate its own replication (33, 34)
and enhance oncolysis (35, 36). By engineering viruses to express
autophagy-inducing genes, such as Beclin-1 (37) and mTOR path-
way regulators (38, 39), improved therapeutic outcomes can be
achieved. This approach may be particularly useful for treating
apoptosis-resistant types of cancer, thus warranting further devel-
opment toward clinical application. Lastly, some OVs can exert
indirect mechanisms of tumor killing, including tumor vascu-
lar shutdown (40, 41) and the induction of antitumor immune
responses, the latter of which is described in further detail in the
following section.
INDUCTION OF ANTITUMOR IMMUNE RESPONSES
The various mechanisms through which OVs are capable of
lysing cancer cells result in the release of tumor associated anti-
gens (TAAs), proinflammatory cytokines, chemokines, and other
danger signals, which facilitates immune cell recruitment and
activation within tumors. In particular, activation and matura-
tion of dendritic cells (DCs) and other antigen presenting cells
(APCs) allow for efficient cross-presentation to T cells, and sub-
sequent initiation of antitumor and antiviral immune responses
(42, 43). However, OVs induce only weak tumor-specific immune
responses, due to premature viral clearance and immunosuppres-
sive regulatory factors within the tumor.
To potentiate their immunogenic effects, genetic engineering
strategies have been used to encode OVs with various cytokines,
immunomodulators, and TAAs (44, 45). Evaluation of the anti-
tumor efficacy of OVs expressing cytokines, such as IL-12, IL-2,
IL-4, IL-18, IL-24, and TNFα, has shown improved therapeu-
tic effects (46–49). One of the most promising cytokines tested
within the OV platform to date, is the granulocyte-macrophage
colony-stimulating factor (GM-CSF), which promotes DC matu-
ration and induces tumor antigen-specific cytotoxic T cells. Three
major viral vectors, Ad, VV, and HSV, armed with GM-CSF have
been demonstrated to enhance antitumor immunity and cytotox-
icity in several clinical trials (50–57). In particular, Talimogene
laherparepvec (T-VEC), a GM-CSF-expressing oHSV-1 that has
recently completed phase III trials in melanoma and head and neck
cancer, are the first to demonstrate efficacy of OV immunother-
apy, with an approximately 30% response rate against systemic
disease, following local injection into accessible tumors (52, 53).
Similar to GM-CSF, Fms-like tyrosine kinase-3 ligand (FLT3L) is
a potent growth factor capable of recruiting and expanding DCs
in vivo (58). OVs expressing FLT3L trigger DC and T cell infiltra-
tion into the tumor and enhance both antitumoral and antiviral
immune responses (42, 59, 60), implicating potential benefits of
using FLT3L as an adjuvant to cancer vaccination. Another strategy
to boost the antitumor response involves genetically engineering
OVs to express inflammatory chemokines, and thus increasing the
number of tumor-infiltrating immune cells. Expression of CCL5,
CCL3, and CCL19 by OVs enhances chemotaxis of immune cells
within the tumor and improves overall therapeutic benefits in vivo
(61–64). Interestingly, distinct effects on virus activity were also
observed, in which VV expressing CCL5 or CCL19 resulted in
increased persistence within the tumor and more rapid clearance
from non-tumor tissues, respectively (61, 65, 66). Finally, cross-
presentation of TAA to T cells through DC activation can also be
achieved by arming OVs with co-stimulatory molecules such as
CD40L (67, 68) and heat shock proteins (69).
A more direct approach to engage antigen-specific T cells is
to engineer OVs to express TAAs, termed oncolytic vaccines (70).
As such, TAAs are overexpressed in the tumor during viral repli-
cation, thus increasing the opportunity for immune responses
to be generated toward tumor-specific antigens. However, suc-
cessful antitumor activity has only been reported using model
tumor antigens such as OVA or LacZ (71, 72) and the same
approach was poorly effective against a self-TAA of low immuno-
genicity (70, 73). Altogether, these results suggest that overex-
pression of a TAA is insufficient to overcome immunosuppres-
sion in the tumor or immunodominant responses against viral
antigens. Therefore, additional approaches are required to boost
TAA-specific responses beyond these barriers. Indeed, significantly
improved therapeutic efficacy can be achieved by adoptive trans-
fer of TAA-specific transgenic T cells (74) or priming the host
with a heterologous vector expressing the TAA (70), prior to
oncolytic vaccination. Both approaches have been demonstrated
to increase TAA-specific T cell frequency, by redirecting the focus
of immune responses to the TAA, rather than the viral vector. Such
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OV-based cancer immunotherapies show promise by harnessing
both oncolytic and antitumor immune-mediated attacks. Clini-
cal evaluation of adoptive T cell transfer and OVs are currently
underway as monotherapies (4, 75), however their success as a
combination therapy has yet to be determined in human cancers.
CHALLENGES OF ONCOLYTIC VIRUS MONOTHERAPY
Oncolytic viruses as a standalone therapeutic intervention have
rarely been shown to induce complete, long-term regression of
established tumors in vivo (76, 77). Tumors can develop multi-
ple barriers to various anticancer therapies, including oncolytic
virotherapy. Here, we detail several mechanisms that may hinder
the therapeutic efficacy of OVs and the challenges they pose to the
development of improved cancer virotherapies.
IMMUNOLOGICAL BARRIERS
The first line of defense against viral infection is the innate immune
cells that patrol,detect, and rapidly eliminate foreign invaders. DCs
express pattern recognition receptors that allow for the detection
and subsequent uptake of viral particles. These activated DCs then
migrate to draining lymph nodes to initiate the development of
adaptive immune responses and to trigger NK cell activation. NK
cells have a predominant role in impeding the early spread of
viruses by directly lysing virally infected cells. Together, DCs and
NK cells produce a range of cytokines that promotes T helper
1 (Th1) cell activity and potent cytotoxic T lymphocyte (CTL)
responses that are necessary for clearing virus-infected cells (78).
Additionally, humoral immune responses, namely the production
of neutralizing antibodies by B cells and plasma cells, provide
several lines of antiviral defense (79). Plasma cells derived from
B1 cells imparts early defense against viral infection by produc-
ing polyspecific antibodies. CD4+ T helper cells then stimulate
naive B cells at later stages, in order to generate memory B cells
and long-lived plasma cells that produce high amounts of spe-
cific neutralizing IgG antibodies. Finally, the complement system,
composed of soluble factors and cell surface receptors, blocks
viral infection by acting on both the innate and adaptive immune
responses. These mechanisms include, enhancing humoral immu-
nity, regulating antibody effector mechanisms, and modulating T
cell function (80).
Altogether, these immunological barriers pose a particular
problem for repeat administration of OVs, by further promot-
ing the development of adaptive antiviral immunity and reducing
of its oncolytic effects. Moreover, a large fraction of the population
has previously been exposed to the naturally occurring viruses that
are commonly employed for generating therapeutic strains. There-
fore, the infectious potential of recognized OVs (e.g., Ad, HSV)
becomes limited by high levels of neutralizing antibodies (81, 82).
These circulating antibodies can limit viruses from ever reaching
the tumor site, especially since some viral particles, including HSV-
1- and murine leukemia virus-derived viruses, are particularly
prone to inactivation by the complement system (83, 84).
TUMOR ENVIRONMENT
Tumors are a heterogeneous assortment of cells, composed of can-
cer cells, stromal cells, and infiltrating leukocytes, which promote
tumor growth and maintain an immunosuppressive environment
(85). Tumor-infiltrating leukocytes (TILs) can negatively regulate
immune responses within the tumor, which include regulatory
T cells (Tregs), myeloid derived suppressor cells (MDSC), and
type 2 macrophages (M2). Their immunosuppressive functions
can be exerted by secretion of cytokines (e.g., IL-10 and TGF-β),
through inhibitory receptors (e.g., CTLA-4 and PD-L1) via cell
contact, and secretion of amino-acid depleting enzymes (arginase
and IDO) in the tumor microenvironment. Tumor cells themselves
also have mechanisms to suppress antitumor immunity, such as
the shedding of NKG2D ligands, MICA/B that blocks NK cell and
T cell function (86) and facilitates the expansion of immunosup-
pressive CD4+ T cells (87). Soluble mediators released by tumor
cells can directly inhibit CTLs, which include TGFβ, IL-10, PGE2,
histamine, hydrogen peroxide, and adenosine (88), in addition
to the hypoxic conditions and low extracellular pH that char-
acterize the tumor environment (89, 90). Therefore, antitumor
immune responses induced by modified-OVs may not be suffi-
cient to combat a highly immunosuppressive tumor environment,
unless additional therapeutic regimens are employed.
Preclinical and clinical evidence indicates that OVs often infect
neoplastic lesions in a heterogeneous and incomplete fashion,
irrespective of administration route and whether viruses are
replication-competent or not (91–93). Physicochemical barriers
to infection, including tumor size (94), the layers of dense intra-
tumoral connective tissue (95), the elevated interstitial pressure
(96), the poorly permissive vasculature (97), and the large areas
of necrosis/calcification (98) play a prominent role in determin-
ing viral dissemination. As a result, oncolytic virotherapy may
result in incomplete eradication of the primary tumor mass or
possibly even promote metastasis of the tumor cells and eventu-
ally leading to recurrence of disease. Similar to what is observed
in chemotherapy and radiotherapy regimens, malignant cells are
also prone to become resistant to oncolytic virotherapy over time.
This is presumably linked to the intrinsic nature of cancers to
exhibit genomic instability and the propensity for accumulating
mutations (99–101).
COMBINING IMMUNOMODULATORY CHEMOTHERAPY WITH
ONCOLYTIC VIROTHERAPY
Chemotherapeutic drugs used in combination with OVs can
potentiate their cytotoxic mechanisms (9), but may also act to
remove barriers to successful oncolytic virotherapy. Counteract-
ing immunological barriers can improve the persistence of viruses
and/or weaken the immunosuppressive forces within the tumor
microenvironment. In this section, we summarize how pharma-
ceutical immunomodulators may be used to promote adaptive
antitumor immune responses induced by OVs.
EVADING ANTIVIRAL IMMUNE RESPONSES
Histone-deacetylase inhibitors (HDACi) are anti-inflammatory
agents that can modulate immune responses to viral infection.
By impeding the type I IFN response, a major component of
the cellular innate antiviral response, HDACi’s can enhance the
spread and antitumor effects of OVs (102). In addition, HDACi’s
may also enhance OV efficacy through initial suppression of
immune cell recruitment and inhibition of inflammatory cell
pathways within NK cells (65). Similarly, a high throughput
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screen of pharmaceutical agents identified a novel drug (Vse1)
that could enhance oncolytic virotherapy by disrupting the IFN-
induced antiviral response and repressing antiviral gene tran-
scripts (103). Another drug that can be used for immune sup-
pression is cyclosphorine A, which markedly increased and pro-
longed the therapeutic effect of reovirus therapy of metastatic
cancer (104, 105). However, the most common immunosup-
pressant drug used in the context of oncolytic virotherapy is
cyclophosphamide (CPA); a chemotherapeutic alkylating agent
that also induces apoptotic cell death. CPA has complex immune-
modulating effects, affecting humoral and cellular mediators of
both the innate and acquired immune responses. These immuno-
suppressive functions have been shown to enhance viral oncolysis
and improve antitumor efficacy of HSV (83, 106, 107), Ad (108),
measles virus (109), reovirus (110, 111), and VV (112). More
specifically, at high doses, CPA has been shown to limit neutral-
izing antibody titers below the limit of detection during herpes
virus hrR3 infection (106). Furthermore, in vivo depletion of com-
plement significantly improved survival of HSV and CPA treated
tumor-bearing rats (83). Global immunosuppression has also been
reported to occur as a result of CPA therapy, including significant
decreases in total white blood cell, lymphocyte, neutrophil, and
monocyte counts in tumor-bearing mice. This was accompanied
by significantly improved survival and decreased tumor volume
in mice treated with both Ad and CPA relative to treatment with
either therapy alone (108). Host lymphodepletion can enhance
the therapeutic efficacy of OVs, as demonstrated by the reduction
of antiviral antibody titers and subsequent promotion of viral
persistence (113).
COUNTERACTING THE IMMUNOSUPPRESSIVE TUMOR ENVIRONMENT
Regulatory T cells and MDSC are TIL populations that are a
major component of the immunosuppressive tumor environment.
Most pharmaceutical strategies that counteract immune resis-
tance mechanisms within the tumor are aimed at depleting these
inhibitory immune cell populations. Reduction of Tregs in cancer
patients has been demonstrated to occur following treatment with
fludarabine and paclitaxel (118, 119). Other chemotherapeutic
drugs shown to decrease Tregs and inhibit their suppressive ability
include CPA, paclitaxel, and temozolomide and cisplatin treat-
ment, which enhances antigen-specific CD8+ T cells in murine
tumor models (114–117). In particular, CPA, paclitaxel, and temo-
zolomide can successfully reduce Treg activity (120–122) when
delivered as metronomic doses (i.e., repetitive, low doses). In the
case of CPA, metronomic doses serve to minimize toxicity and
avoid global immunosuppression resulting from administering
a single, high dose. Comparison of metronomic and maximum
tolerated doses of CPA revealed that deletion of proliferating
tumor-specific CTLs occurred in both dosing schedules. How-
ever, at metronomic doses, slower kinetics of deletion and survival
of cells with a CD43lo “memory” phenotype was observed, result-
ing in potent restimulatory capacity (122). This is supported by
clinical evidence, in which metronomic CPA can deplete Tregs
and restore T and NK cell effector function in advanced cancer
patients (123). In the context of oncolytic virotherapy, precondi-
tioning of mice with either CPA or anti-CD25 mAb to deplete Tregs
enhances therapeutic benefits of oncolytic reovirus and VSV (111,
124). Furthermore, early clinical evaluation of metronomic CPA
and oncolytic Ad combination treatment demonstrates improved
antitumor efficacy, resulting from increased cytotoxic T cells and
induced Th1 type immunity (125).
In healthy tissues, MDSCs play a protective role during inflam-
mation to maintain homeostasis of pathogenic immune responses.
However, accumulation of MDSCs in the tumor environment is
also capable of promoting tumor growth by inhibiting antitumor
effector T cell responses. They exert their effects through multiple
immunomodulatory roles, such as upregulating the production of
immune-suppressive factors (e.g., nitric oxide and reactive oxygen
species), overexpressing anti-inflammatory cytokines (e.g., TGF-
β and IL-10), suppressing proliferation and cytokine production
by T cells and NK cells, and inducing apoptosis of CD8+ T cells
(126). Furthermore, MDSCs can mediate the expansion of other
immunosuppressive Treg and M2 populations (127–129). Numer-
ous chemotherapeutic drugs have been used to deplete MDSCs,
including gemcitabine, sunitinib, 5-FU, docetaxel, and retinoic
acid (130–134). Combinations of OVs with various MDSC deplet-
ing drugs have been investigated at length, overall demonstrating
improved survival in preclinical studies. The therapeutic ben-
efits of using these OV-drug combinations depend on several
factors, including the type of OV-drug combination used, the
timing, frequency, and dosage of drug administration, and the
cancer type targeted. However, given that these immunomodula-
tory drugs have other antitumoral effects, few studies have directly
assessed their ability to deplete MDSCs in each context (135, 136).
Notably, use of these drugs to deplete MDSCs can also positively
or negatively affect oncolytic virotherapy. For instance, metro-
nomic treatment of either gemcitabine or 5-Fu with oncolytic Ad,
increases viral uptake by upregulating the expression of internal-
ization receptors (137). Moreover, sunitinib negatively regulates
the antiviral OAS-RNase L pathway, thus enhancing viral replica-
tion of VSV in tumors (138). In contrast, concurrent therapy of
5-Fu with HSV-1 inhibits virus replication and oncolysis (139).
Therefore, optimization of these OV-drug combination strategies
to benefit both the oncolytic and antitumor immune effects of
OVs requires further investigation.
Given that chemotherapies have non-specific effects, some
drugs can also modulate tumor cell immunogenicity to bene-
fit oncolytic virotherapy. For example, paclitaxel can upregulate
MHC class I expression and antigen-processing machinery com-
ponents (140). 5′-aza-2′-deoxycytidine and 5-Fu have been shown
to enhance tumor antigen expression (141–143), while Ara-C
(cytosine arabinoside) treatment results in the induction of co-
stimulatory molecules that provide a greater chance of effective
immune activation (144, 145). Furthermore, both doxorubicin
and Ara-C decreases the expression of immune checkpoint mol-
ecules, such as PD-L1, blocking their inhibitory effects on infil-
trating T cells (146, 147). Some drugs, namely CPA, 5-Fu, and
Dacarbazine, can sensitize tumor cells to CD8+ T cell-mediated
apoptosis (148, 149), and thus may serve as ideal candidates for
therapeutic combinations with various cancer immunotherapies.
EVALUATING THE LANDSCAPE OF OV-DRUG COMBINATIONS
Tumor cell heterogeneity as a result of DNA instability promotes
the natural selection of tumor progeny with greater proliferative
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capacity and invasive potential (150, 151). As a result, treatment
methods that address a singular therapeutic strategy may be insuf-
ficient to completely eliminate tumor growth. OV-drug combi-
natorial strategies present countless different permutations, and
consequently, numerous possibilities to mobilize multiple and
simultaneous therapeutic approaches. However, previous stud-
ies that report synergistic outcomes from combining OVs with
chemotherapy largely focus on a single therapeutic aspect, such
as their effect on viral spread and persistence, cytotoxicity, or
immunomodulation. As we become more familiar with how var-
ious chemotherapeutic drugs function, it is increasingly apparent
that many drugs act in a multi-mechanistic fashion. In other
words, chemotherapeutic agents can impact multiple biological
processes, which in turn can further potentiate OV-drug interac-
tions. For instance, rapamycin and its analogs have been shown
to alter mTOR signaling to increase the tropism of OVs (152),
inhibit angiogenesis (153), induce autophagy (32), and inhibit the
function of M2 macrophages (154). HDACis such as Trichostatin
A alter chromatin structure and regulate gene expression on an
epigenetic level, leading to a wide range of biological effects like
promoting tumor antigen presentation (155), improving tumor
susceptibility to OVs (156–158), down-regulating the antiviral
response (159), and targeting tumors and tumor vasculature (160).
Lastly, receptor tyrosine kinase inhibitor sunitinib can down-
regulate antiviral pathways (138), deplete MDSCs (131), inhibit
M2 macrophages (161), and reduce tumor vascularization (162).
Therefore, rather than evaluating individual therapeutic strategies
that are complementary to oncolytic viral activity, combinatorial
strategies using chemotherapeutic drugs should take into account
of their entire functional repertoire, in order to determine the best
overall approach. However,given the complex, interconnected bio-
logical pathways that regulate viral infection and tumor growth,
assessing OV-drug combinations is not a simple task.
CHALLENGES OF COMBINATION THERAPY
As previously mentioned, the biological pathways that OVs manip-
ulate to support their replication are similar to those utilized by
cancer cells to become increasingly malignant (e.g., defects in the
IFN pathway, apoptotic-resistance, immune suppression). In fact,
targeting certain pathways with chemotherapy will also, by asso-
ciation, compromise the replicative capacity of OVs. As a result,
discernable conflicts between virus-enabled therapeutic strategies
and drug-enabled therapeutic strategies may limit the extent to
which the two can be combined. For example, viruses require
actively dividing cells to maximize their replicative efficiency, while
many anticancer agents are either cytotoxic or cytostatic with
death-inducing or anti-proliferative effects, respectively (9). Fur-
thermore, studies suggest that the leaky vasculature of tumors
is exploited by viruses to successfully extravasate into the tumor
site (163, 164). Some OVs can actually stimulate angiogenesis
to increase vascular permeability in tumors (165). Thus, anti-
angiogenic therapy may thus adversely affect the localization of
OVs to the tumor microenvironment. Finally, modulation of the
host immune response through chemotherapy may conflict with
the therapeutic function of the oncolytic virus. For instance, low
dose CPA may remove immunosuppressive cells such as Tregs to
improve vaccine-induced adaptive antitumor immune responses;
however, it also promotes the antiviral immune response, leading
to early viral clearance (166). Conversely, high dose CPA may
enhance viral oncolysis through wide-spread immunosuppres-
sion of the innate and adaptive antiviral immune response, but
also completely abrogate the antitumor immune response (167).
These conflicting mechanisms (apoptosis vs. viral replication,anti-
angiogenesis vs. viral trafficking, antiviral immune responses vs.
antitumor immune responses) are further compounded when
we consider that drugs often regulate multiple biological host
processes. Nevertheless, OV-drug combinations that demonstrate
therapeutic incompatibility are still efficacious in some models.
In these cases, it is likely that the number of beneficial interac-
tions between OVs and drugs outweigh the number of detrimental
effects, resulting in an overall enhanced therapeutic outcome.
While current combinatorial strategies have been able to iden-
tify unique synergistic OV-drug platforms, the challenge going
forward is to obtain a greater understanding of OV-drug inter-
actions. Based on these exploratory findings, we will be able to
identify optimal treatment conditions that minimize therapeutic
trade-offs.
SUCCESSFUL COMBINATION THERAPY IS CONTEXT-DEPENDENT
As previously mentioned, seemingly incompatible OV-drug com-
binations have shown therapeutic efficacy because their positive
effects outweigh their negative effects. Based on these initial stud-
ies, it is also apparent that some factors can tip the OV-drug
dynamic in favor of enhanced cancer therapy in one context, but
also have the reverse effects in another. For instance, concurrent
administration of 5-FU has been shown to inhibit the replication
of wild-type HSV-1 strain KOS (139); however, the same drug has
been shown to actually enhance viral replication of NV1066 (HSV-
1 with a single copy of ICP0, ICP4, and γ134.5 deleted) in pancre-
atic cancer cell lines (168). Interestingly, growth arrest and DNA
damage as a result of 5-FU administration upregulates the expres-
sion of DNA damage-inducible protein GADD34, which bears
significant homology with the deleted γ134.5. As a consequence,
GADD34 can functionally replaceγ134.5, prevent premature shut-
off of protein synthesis, and thus enhance viral replication (169).
Another factor that is demonstrated to be context-dependent
is the schedule and dosage of drug delivery given during OV-
drug combination therapy. However, if their costs and benefits to
oncolytic virotherapy are clear, we may adjust these variables for
an optimized therapeutic outcome. For example, VEGF blockade
through a variety of small-molecule chemotherapeutics decreases
the tumor uptake of systemic oncolytic HSV, but can actually
improve the treatment of sarcoma-bearing mice if anti-angiogenic
therapy is given subsequent to virus administration (170).
Overall, specific strategies to optimize OV-drug combinations
depend on the circumstances of the model system. To this point,
we have previously shown that systemic vaccination with recom-
binant VSV encoding the xenogeneic TAA, human dopachrome
tautomerase (hDCT), was unable to induce robust tumor-specific
immunity because the host immune response was predominantly
redirected toward viral antigens expressed on the vector. There-
fore,by adopting a heterologous prime-boost system whereby mice
were initially primed with recombinant Ad-hDCT and boosted
with VSV-hDCT, substantive immunity was generated against the
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tumor, while the antiviral response to VSV was dampened (70).
The HDACi, MS-275, is an ideal candidate for combination ther-
apy with this prime-boost system because it has previously been
shown to decrease IFN responsiveness in tumors, thus augment-
ing viral oncolysis. However, MS-275 is also immunosuppressive
and resulted in abrogation of the priming response if given con-
currently with Ad-hDCT. Alternatively, if drug treatment was
given concurrently with VSV-hDCT, the boosting response was
unaffected and over 60% of mice challenged with intracranial
melanoma were cured (171). Since MS-275 is an HDACi; an epige-
netic modifier that can modify the expression of numerous genes,
its range of effects have not yet been fully elucidated. As such,
many unknown functional properties may still exist, especially in
the context of oncolytic virotherapy.
CONCLUDING REMARKS
War strategy dictates methods in which to arrange and maneu-
ver military forces during armed conflicts. Using the available
resources and landscape to your advantage is a key aspect to defeat-
ing the enemy. The analogy of OVs as fighters, “targeting” cancer
cells and being “armed” with various genes, is commonplace in
the literature. Its ability to induce antitumor immune responses
is akin to the call for air support, bringing in additional fighters
that can help to identify and target enemy forces. The introduc-
tion of chemotherapeutic drugs to the battlefield is then, chemical
warfare; a wide-spread, indiscriminate weapon. With our various
forces at hand, how do we determine the best strategy to defeat
our opponents? As with any war strategy game, finding the best
approach begins with knowing the enemy (type of cancer), know-
ing our forces (viruses, drugs, and immune cells), their strengths
and weaknesses (function), and finally how they interact with each
other on the battlefield (combination therapy). Before you make
a move, you postulate various scenarios in which your opponent
may attack, but also how you can take the advantage. In a similar
fashion, to identify the most suitable approach to OV-drug com-
bination therapies, we should adopt a broader perspective to the
treatment of cancer. Then and only then, will we not only win
some battles, but we may also win the war.
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